CAR-T therapy works for some blood cancers, but can we make it work for brain tumours?

July 26, 2018 by Peter Abel, The Conversation
T-cells (red) attacking cancer cells (white). Credit: Meletios Verras/

A powerful new anti-cancer therapy, called CAR-T, has shown great promise in treating blood cancers. Last year, the Food and Drug Administration approved the treatment for acute lymphoblastic leukaemia, and the results have been very promising, with remission rates of up to 83% for the very worst case patients, whose disease had returned following conventional treatments.

CAR-T (chimeric antigen receptor T-cell) therapy uses the body's immune system to destroy cancer cells. It involves taking a patient's T-cells (a type of immune cell) and genetically altering them so they attack cancer cells rather than invading organisms, such as bacteria. Large numbers of these CAR-T cells are grown in the lab before being infused into the patient.

With the recent success in mind, it is tempting to consider whether this approach would work in other cancers, particularly cancers that are notoriously difficult to treat, such as . Unfortunately, this has not happened yet, and the reason is to do with the nature of cancer itself.

Cancer is not just one disease but many, each requiring a different treatment, and tumour treatment has a dismal history, with high-grade glioblastoma patients having an average survival rate of one year after diagnosis.

Why so difficult?

So what is the problem with treating solid tumours and brain tumours in particular? The answer lies in the nature of the disease and the treatment. In leukaemia, there is a single, identifiable : a molecule on the surface of the tumour cell called CD19. It's a relatively straightforward task to engineer a CAR-T cell to attack that target and destroy the tumour.

In high-grade brain cancers (where spread and grow more quickly), the tumour is heterogeneous, which means the target molecules on the are constantly changing over the course of the disease. In different areas of the same tumour you will have different target molecules, so creating a CAR-T cell to attack the tumour becomes an impossible task.

Also, high-grade brain tumours build a network of to support and feed the tumour as it grows and spreads to other areas of the brain, in a process known as "angiogenesis". Understandably, this makes some brain tumours very difficult to treat and remove.

Another feature of brain tumours involves another type of immune cell called the regulatory T-cell. These are the cells that stop our immune system from attacking our own bodies. (When they go wrong they cause autoimmune diseases such as rheumatoid arthritis.) Brain tumours can hijack these cells to create an immunosuppressive micro-environment for the tumour to live in. Even if could get to the site of the tumour, they would be "switched off" by the actions of these regulatory T-cells, and the tumour would be safely protected from the attack.

Dismantling safe spaces

The outlook for using immunotherapy to treat brain looks poor with several barriers to be overcome, but let's look again at CAR-T therapy.

We can create a specific immune cell to attack a specific target and fourth-generation CAR-T cells can be produced to attack two or more specific targets – but this isn't enough. So instead of focusing on the moving target of the tumour cell, perhaps we should look at other targets.

The processes of angiogenesis (the development of new blood vessels) and immuno-suppression are driven by cells that have their own unique molecular characteristics, so let's target these areas. Let's take away the "safe space" the tumour has created for itself by destroying the micro-environment of the tumour, allowing our immune cells to do their job of destroying it.

There is a major problem that would need to be overcome for this to work, which is systemic toxicity – the result of the engineered CAR-T cells attacking the wrong healthy target cells. The last thing we need is for our CAR-T cells to destroy new blood vessels or all regulatory T cells.

What we need are -specific targets for the newly created blood vessels and the immune-suppressing T-. Finding these will be the focus of my future research.

Explore further: Teamwork between cells fuels aggressive childhood brain tumor

Related Stories

Teamwork between cells fuels aggressive childhood brain tumor

July 2, 2018
Scientists have discovered that cancerous cells in an aggressive type of childhood brain tumour work together to infiltrate the brain, and this finding could ultimately lead to much needed new treatments, according to a new ...

Blood vessel-forming cells involved in aggressive brain tumour

June 20, 2018
A type of highly malignant brain tumour contains a large number of cells involved in the formation of new blood vessels, helping it proliferate and spread. Targeting these cells could hinder tumour growth, according to new ...

Breaking through a tumor's defenses

June 7, 2018
In research published today, Babraham Institute researchers have shown that some tumours use not one but two levels of protection against the immune system. Knocking out one level boosted the protective effects of the second ...

Tumor-trained T cells go on patrol

May 15, 2017
'Tumour-trained' immune cells - which have the potential to kill cancer cells - have been seen moving from one tumour to another for the first time. The new findings, which were uncovered by scientists at Australia's Garvan ...

Virus could help treat advanced cancers

June 12, 2018
Early results from a small-scale clinical trial have revealed the potential of a virus to treat some advanced cancers.

New drug to supercharge immune cells in the fight against cancer

September 28, 2017
A new cancer treatment with the ability to normalise tumour blood vessels and boost the body's immune system has been developed by researchers from The University of Western Australia and the Harry Perkins Institute of Medical ...

Recommended for you

Healthy diets linked to better outcomes in colorectal cancer

October 20, 2018
Colorectal cancer patients who followed healthy diets had a lower risk of death from colorectal cancer and all causes, even those who improved their diets after being diagnosed, according to a new American Cancer Society ...

Scientists to improve cancer treatment effectiveness

October 19, 2018
Together with researchers from the University of Nantes and the University of Reims Champagne-Ardenne in France, experts from the National Research Nuclear University MEPhI have recently developed a quantum dot-based microarray ...

Why some cancers affect only young women

October 19, 2018
Among several forms of pancreatic cancer, one of them specifically affects women, often young. How is this possible, even though the pancreas is an organ with little exposure to sex hormones? This pancreatic cancer, known ...

Mutant cells colonize our tissues over our lifetime

October 18, 2018
By the time we reach middle age, more than half of the oesophagus in healthy people has been taken over by cells carrying mutations in cancer genes, scientists have uncovered. By studying normal oesophagus tissue, scientists ...

Study involving hundreds of patient samples may reveal new treatment options of leukemia

October 17, 2018
After more than five years and 672 patient samples, an OHSU research team has published the largest cancer dataset of its kind for a form of leukemia. The study, "Functional Genomic Landscape of Acute Myeloid Leukemia", published ...

A 150-year-old drug might improve radiation therapy for cancer

October 17, 2018
A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more sensitive to radiation therapy, according to a recent study led by researchers at The Ohio State University Comprehensive Cancer ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.